Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Raquel Bouça-Machado
Based on 10 articles published since 2010
(Why 10 articles?)
||||

Between 2010 and 2020, Raquel Bouça-Machado wrote the following 10 articles about Parkinson Disease.
 
+ Citations + Abstracts
1 Review Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. 2020

Bouça-Machado, Raquel / Duarte, Gonçalo S / Patriarca, Maria / Castro Caldas, Ana / Alarcão, Joana / Fernandes, Ricardo M / Mestre, Tiago A / Matias, Ricardo / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal. · CNS-Campus Neurológico Sénior Torres Vedras Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal. · Center for Evidence-Based Medicine, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal. · Department of Pediatrics Santa Maria Hospital Lisbon Portugal. · Parkinson's disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute University of Ottawa Brain and Research Institute Ottawa Ontario Canada. · Champalimaud Research and Clinical Centre Champalimaud Centre for the Unknown Lisbon Portugal. · Human Movement Analysis Lab Escola Superior Saúde-Instituto Politécnico de Setúbal Setúbal Portugal. ·Mov Disord Clin Pract · Pubmed #32071930.

ABSTRACT: Background: Functional mobility (FM) is a person's ability to move to accomplish activities of daily living; it bridges the concepts of mobility and functional ability. There is frequently a loss of FM in Parkinson's disease (PD). Several instruments have been used to assess this concept in PD; however, there is no consensus on which are the most appropriate. Objective: We aimed to identify and critically appraise which measurement instruments have been used to assess FM. Methods: A systematic review was conducted using the databases CENTRAL, MEDLINE, Embase, and PEDro from their inception to January 2019 to identify all observational and experimental studies conducted in PD or atypical parkinsonism that included an FM assessment. Two reviewers independently screened citations, extracted data, and assessed clinimetric properties. Results: We included 95 studies that assessed FM in PD. Fifty-five (57.9%) studies mentioned FM in the article, and 39 (41.1%) specified the measurement tools used to evaluate FM. FM was the primary outcome in 12 (12.6%) studies. The Timed Up and Go test was the most frequently used measurement tool. Only one study presented a definition of FM. Several overlapping terms were used, the most common being mobility. Conclusion: Several studies reported the use of FM measurement tools in PD, though with frequent misconceptions, an inadequate context of use, or suboptimal assessment. We propose the establishment of the concept of FM applied to PD, followed by the adequate clinimetric validation of existing measurement tools to provide a comprehensive and reliable evaluation of FM in PD.

2 Review Physical Activity, Exercise, and Physiotherapy in Parkinson's Disease: Defining the Concepts. 2020

Bouça-Machado, Raquel / Rosário, Ana / Caldeira, Daniel / Castro Caldas, Ana / Guerreiro, Daniela / Venturelli, Massimo / Tinazzi, Michele / Schena, Federico / J Ferreira, Joaquim. ·Instituto de Medicina Molecular Lisbon Portugal. · CNS-Campus Neurológico Sénior Torres Vedras Portugal. · Laboratory of Clinical Pharmacology and Therapeutics Faculdade de Medicina, Universidade de Lisboa Lisbon Portugal. · Department of Neurological and Movement Sciences University of Verona Verona Italy. ·Mov Disord Clin Pract · Pubmed #31970204.

ABSTRACT: Background: Exercise is gaining extreme relevancy as a new therapeutic intervention for Parkinson's disease (PD). However, the frequent misuse of the concepts exercise, physiotherapy, and physical activity limits the possibility of summarizing research findings. This review aims to clarify these concepts and summarize the evidence on exercise in PD. Methods: We critically appraised physical activity-related concepts and conducted a systematic review of clinical trials evaluating exercise interventions in PD. Additionally, we discussed the implications for PD clinical practice and research. Results: Exercise is a subset of physical activity, and a major component of physiotherapy for PD management, having as the main goal to improve physical fitness. The appraisal of the 83 identified clinical trials found high variability in exercise interventions. Multimodal exercise was the most studied, and 60 minutes, two times/week for 12 weeks, the most reported prescription parameters. Conclusion: The best available evidence recommends increasing physical activity levels in PD. Exercise and physiotherapy programs seem the most efficacious strategies to achieve this goal. As a result of the heterogeneity in the type and manner exercise is prescribed, it is not possible to propose strong recommendations for exercise in PD. We believe that, in addition to the clarification of concepts here presented, a collaborative and rigorous work of different areas of knowledge is needed.

3 Review Palliative Care for Patients and Families With Parkinson's Disease. 2017

Bouça-Machado, Raquel / Titova, Nataliya / Chaudhuri, K Ray / Bloem, Bas R / Ferreira, Joaquim J. ·Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. · Federal State Budgetary Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia. · National Parkinson Foundation International Centre of Excellence, Kings College and Kings College Hospital, London, United Kingdom; Maurice Wohl Clinical Neuroscience Institute, Kings College, London, United Kingdom; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) and Dementia Unit at South London and Maudsley NHS Foundation Trust, London, United Kingdom. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; CNS-Campus Neurológico Sénior, Torres Vedras, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. Electronic address: joaquimjferreira@gmail.com. ·Int Rev Neurobiol · Pubmed #28554419.

ABSTRACT: Parkinson's disease is the second most common neurodegenerative disease worldwide. There is widespread consensus that Parkinson patients, their carers, and clinicians involved in their care would benefit from a fully integrated, need-based provision of palliative care. However, the concept of palliative care in Parkinson's disease is still poorly defined and, consequently, poorly implemented into daily clinical practice. A particular challenge is the gradually progressive nature of Parkinson's disease-with insidiously increasing disability-making it challenging to clearly define the onset of palliative care needs for Parkinson patients. As people with Parkinson's disease are now living longer than in the past, future research needs to develop a more robust evidence-based approach to clarify the disease events associated with increased palliative care needs, and to examine these, prospectively, in an integrated palliative care service. The modern palliative care outlook, termed "simultaneous care,",is no longer restricted to the final stage of disease. It involves incorporating a continuity of care, effective management of the chronic-palliative interface, and a multidisciplinary network of professionals working both in the community and in specialized clinics, with active involvement of caregivers. Although promising, there is still a need to demonstrate the effectiveness of palliative care for patients with Parkinson's disease.

4 Article Treating Patients Like Athletes: Sports Science Applied to Parkinson's Disease. 2020

Bouça-Machado, Raquel / Venturelli, Massimo / Tinazzi, Michele / Schena, Federico / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. · CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. · Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. · Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. ·Front Neurol · Pubmed #32300330.

ABSTRACT: The evidence demonstrating the benefits of exercise is indisputable for healthy subjects, and more recently, it is growing for Parkinson's disease (PD) patients. Due to its easy access, low cost, social facilitation and, above all, the symptomatic effect, clinical exercise may have a profound impact on PD management. Especially considering that in recent decades there have been no major advances from the pharmacological point of view. Despite this, clinical exercise use it stills limited by the existent flaws in the available evidence supporting its use and guiding its prescription as a PD therapeutic intervention. We believe that a approach from the most relevant scientific and clinical fields is crucial to establish the use of clinical exercise in PD patients' routine care. Therefore, in this viewpoint, we aim to highlight the importance of clinical exercise as a therapeutic intervention in PD, and particularly of the benefits of applying sports science principles to potentiate the use of clinical exercise as a therapeutic intervention in PD management.

5 Article Swimming is compromised in Parkinson's disease patients. 2020

Neves, Maria Ana / Bouça-Machado, Raquel / Guerreiro, Daniela / Caniça, Verónica / Pona-Ferreira, Filipa / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Lisbon, Portugal. · CNS - Campus Neurológico Sénior, Torres Vedras, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. ·Mov Disord · Pubmed #31799732.

ABSTRACT: BACKGROUND: A recent survey reported a high risk of drowning in Parkinson's disease (PD) patients. This study intended to assess PD patients' swimming ability and explore the disease-related characteristics that may affect this. METHODS: A cross-sectional study was conducted in idiopathic PD patients. The assessment included swimming in 2 different styles and the evaluation of isolated technical gestures. The primary outcome was the frequency of patients who were able to swim. Limb coordination, blockage episodes, and capacity to maintain the body in a horizontal position were also evaluated. RESULTS: Thirteen patients were evaluated. Three patients were able to swim according to the predefined definition. The inability to maintain the horizontal position and floatability were the main reasons identified for the decrease in swimming performance. CONCLUSIONS: Swimming ability is compromised in some PD patients. Further studies are needed to evaluate the global frequency of swimming difficulties in PD patients and their contributing factors. © 2019 International Parkinson and Movement Disorder Society.

6 Article Reporting and methodological quality of clinical trials on exercise therapy for Parkinson's disease. 2019

Silva, Cláudia M / Travessa, André M / Bouça-Machado, Raquel / Caldeira, Daniel / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Lisboa, Portugal. Electronic address: claudiamouratosilva@gmail.com. · Instituto de Medicina Molecular, Lisboa, Portugal; Serviço de Genética Médica, Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Portugal; Instituto de Histologia e Biologia do Desenvolvimento, Faculdade de Medicina, Universidade de Lisboa, Portugal. Electronic address: at1@campus.ul.pt. · Instituto de Medicina Molecular, Lisboa, Portugal; CNS - Campus Neurológico Sénior, Torres Vedras, Portugal. Electronic address: raquelbouca@gmail.com. · Instituto de Medicina Molecular, Lisboa, Portugal; Centro Cardiovascular da Universidade de Lisboa - CCUL, Faculdade de Medicina, Universidade de Lisboa, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal. Electronic address: dgcaldeira@hotmail.com. · Instituto de Medicina Molecular, Lisboa, Portugal; CNS - Campus Neurológico Sénior, Torres Vedras, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal. Electronic address: joaquimjferreira@gmail.com. ·Parkinsonism Relat Disord · Pubmed #31760307.

ABSTRACT: BACKGROUND: Exercise therapy is becoming extremely relevant as a new efficacious intervention in multiple medical fields. Although several clinical trials have reported benefits of exercise therapy for Parkinson's disease (PD), recommendations and prescriptions for its use in clinical practice remain limited. OBJECTIVES: To evaluate the methodological quality and publication rate of clinical trials on exercise therapy for PD. METHODS: We analyzed all clinical trials assessing exercise therapy for PD registered in the WHO International Clinical Trials Registry Platform and the ClinicalTrials.gov registries, from 2000 to 2017. We evaluated the methodological quality of trials using the Cochrane Risk of Bias criteria. RESULTS: A total of 236 clinical trials were identified. Only 70 (29.7%) trials reported their findings, and 61 (25.8%) had results published in scientific journals. Most trials had an unclear risk of bias concerning incomplete and selective outcome reporting and lacked data on the randomization process, allocation concealment, blinding of participants and personnel, and outcomes assessors. Aerobic capacity was the most frequent type of exercise intervention. CONCLUSIONS: Although a large number of trials on exercise are registered in international portals, the quality of reporting remains suboptimal and only a quarter of trials have their results published in scientific journals. These two factors, in addition to the heterogeneity of the interventions tested and the unsatisfactory reported methodological quality of most trials, compromise the interpretation of study results. Therefore, higher quality clinical trials reports are needed to establish exercise as part of the PD armamentarium.

7 Article What is Functional Mobility Applied to Parkinson's Disease? 2018

Bouça-Machado, Raquel / Maetzler, Walter / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Lisbon, Portugal. · CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. · Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. ·J Parkinsons Dis · Pubmed #29480225.

ABSTRACT: Although yet poorly defined and often misused, the concept of functional mobility has been used in research studies as a more global and ecological outcome of patients' health status. Functional mobility is a person's physiological ability to move independently and safely in a variety of environments in order to accomplish functional activities or tasks and to participate in the activities of daily living, at home, work and in the community. Parkinson's disease (PD) has a direct impact on patients' motor control and on mobility in general. Even with optimal medical management, the progression of PD is associated with mounting impairments at different levels of body function, causing marked limitations in a wide variety of activities, as well as a severe disability and loss of autonomy. Despite this, for everyday functioning PD patients need to have a good functional mobility that allow them to get around effortlessly in a reasonable amount of time to access to the same environments as others. This paper reviewed the concept of functional mobility applied to PD. This was done through an International Classification of Functioning and Disability (ICF) perspective. Recommendations to address the known factors that contribute to a poor functional mobility were outlined while suggestions for clinical practice and research were made.

8 Article Why Palliative Care Applies to Parkinson's Disease. 2018

Bouça-Machado, Raquel / Lennaerts-Kats, Herma / Bloem, Bastiaan / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Lisbon, Portugal. · CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. · Radboud University Medical Center, Department of Neurology, Department of Anaesthesiology, Pain and Palliative Care, Nijmegen, The Netherlands. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, The Netherlands. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. ·Mov Disord · Pubmed #29436747.

ABSTRACT: -- No abstract --

9 Minor Risk of drowning in people with Parkinson's disease. 2018

Neves, Maria Ana / Bouça-Machado, Raquel / Guerreiro, Daniela / Caniça, Verónica / Ferreira, Joaquim J. ·Instituto de Medicina Molecular, Lisbon, Portugal. · Campus Neurológico Sénior (CNS), Torres Vedras, Portugal. · Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. ·Mov Disord · Pubmed #30207614.

ABSTRACT: -- No abstract --

10 Minor Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease. 2017

Correia Guedes, Leonor / Reimão, Sofia / Paulino, Patrícia / Nunes, Rita G / Bouça-Machado, Raquel / Abreu, Daisy / Gonçalves, Nilza / Soares, Tiago / Fabbri, Margherita / Godinho, Catarina / Pita Lobo, Patrícia / Neutel, Dulce / Quadri, Marialuisa / Coelho, Miguel / Rosa, Mario M / Campos, Jorge / Outeiro, Tiago F / Sampaio, Cristina / Bonifati, Vincenzo / Ferreira, Joaquim J. ·Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria-CHLN, Lisbon, Portugal. · Clinical Pharmachology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Neurological Imaging Department, Hospital de Santa Maria-CHLN, Lisbon, Portugal. · Instituto de Biofísica e Engenharia Biomédica, Faculty of Science, University of Lisbon, Portugal. · Faculty of Science and Technology, Nova University of Lisbon, Campus da Caparica, Portugal. · Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands. · Laboratory of Clinical Pharmachology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · CEDOC, Chronic Diseases Research Centre, Nova Medical School, Nova University of Lisbon, Lisboa, Portugal. · Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Gottingen, Germany. · Max Planck Institute for Experimental Medicine, Gottingen, Germany. · CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. ·Mov Disord · Pubmed #28686310.

ABSTRACT: -- No abstract --